Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBDF 101

Drug Profile

BBDF 101

Alternative Names: Batten-1; BBDF-101

Latest Information Update: 10 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beyond Batten Disease Foundation
  • Developer Beyond Batten Disease Foundation; Theranexus
  • Class
  • Mechanism of Action Alpha-glucosidase inhibitors; Autophagy stimulants; Glucosylceramide synthase inhibitors; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Neuronal ceroid lipofuscinosis

Most Recent Events

  • 09 May 2023 Theranexus and Beyond Batten Disease Foundation plans a phase III trial for Neuronal ceroid lipofuscinosis in USA and Europe (PO, Capsule)
  • 02 Mar 2021 Beyond Batten Disease Foundation (BBDF) enters into an agreement with Actelion Pharmaceuticals to provide Miglustat for the development of BBDF 101 for Batten disease .
  • 11 Aug 2020 Theranexus plans a phase I-III trial for Neuronal-ceroid-lipofuscinosis (Batten disease) in 2021, In the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top